A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011

Pharmaceuticals - Tập 6 Số 11 - Trang 1335-1346
Ian Morrissey1, Meredith Hackel2,3, Robert E. Badal2,3, Samuel K. Bouchillon2,3, Stephen Hawser1, Douglas J. Biedenbach2,3
1IHMA Europe Sàrl, 9A Route de la Corniche, Epalinges 1066, Switzerland
2International Health Management Associates, Inc
3Schaumburg, IL 60173, IL, USA

Tóm tắt

Surveillance of antimicrobial agent resistance provides important information to guide microbiologists and infectious disease specialists understanding of the control and the spread of resistance mechanisms within the local environment. Continued monitoring of antimicrobial resistance patterns in the community and in local hospital environments is essential to guide effective empiric therapy. The Study for Monitoring Antimicrobial Resistance Trends (SMART) has monitored the in vitro susceptibility patterns of clinical Gram-negative bacilli to antimicrobial agents collected worldwide from intra-abdominal infections since 2002 and urinary tract infections since 2009. Resistance trends, with a particular focus on carbapenem resistance and the rate of extended-spectrum β-lactamases (ESBLs), were analyzed. Isolates from intra-abdominal infections (n = 92,086) and urinary-tract infections (n = 24,705) were collected and tested using Clinical and Laboratory Standards Institute methods. This review presents carbapenem susceptibility and ESBL rates over ten years of SMART study analysis, including key publications during this period. The SMART study has proved to be a valuable resource in determining pathogen prevalence and antibiotic susceptibility over the last ten years and continues to provide evidence for regulatory susceptibility breakpoints and clinical decision making.

Từ khóa


Tài liệu tham khảo

Hawser, 2012, Surveillance programmes and antibiotic resistance: Worldwide and regional monitoring of antibiotic resistance trends, Antibiotic Resist., 211, 31, 10.1007/978-3-642-28951-4_3

Felmingham, 2005, The Alexander Project: the benefits from a decade of surveillance, J. Antimicrob. Chemother., 56, ii3, 10.1093/jac/dki297

(2012). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards—Ninth Edition, Clinical Laboratory Standards Institute.

(2013). Performance Standards for Antimicrobial Susceptibility Testing, Twenty-second Informational Supplement, Clinical and Laboratory Standards Institute (CLSI).

Hawser, 2009, In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005–2007: Results from the SMART study, Int. J. Antimicrob. Agents., 34, 585, 10.1016/j.ijantimicag.2009.07.013

Lascols, 2012, Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: A snapshot of extended-spectrum β-lactamases throughout the world, J. Clin. Microbiol., 50, 1632, 10.1128/JCM.06115-11

Hawser, 2011, Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates, Antimicrob. Agents Chemother., 55, 3917, 10.1128/AAC.00070-11

Yong, 2009, Characterization of a new metallo-β-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India, Antimicrob. Agents Chemother., 53, 5046, 10.1128/AAC.00774-09

Castanheira, 2010, Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006–2007, Antimicrob. Agents Chemother., 55, 1274, 10.1128/AAC.01497-10

Kumarasamy, 2010, Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: A molecular, biological, and epidemiological study, Lancet Infect. Dis., 10, 597, 10.1016/S1473-3099(10)70143-2

Lascols, 2011, Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: Data from the SMART study (2009), J. Antimicrob. Chemother., 66, 1992, 10.1093/jac/dkr240

Sheng, 2013, Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: Results of the study for Monitoring Antimicrobial Resistance Trends (SMART), Antimicrob. Agents Chemother., 57, 2981, 10.1128/AAC.00971-12

Yang, 2010, Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in China: the 2002–2009 Study for Monitoring Antimicrobial Resistance Trends (SMART), Int. J. Antimicrob. Agents, 36, 507, 10.1016/j.ijantimicag.2010.09.001

Hawser, 2010, Antibiotic susceptibility of intra-abdominal infection isolates from Indian hospitals during 2008, J. Med. Microbiol., 59, 1050, 10.1099/jmm.0.020784-0

Hawser, 2011, Trending eight years of in vitro activity of ertapenem and comparators against Escherichia coli from intra-abdominal infections in North America—SMART 2002–2009, J. Chemother., 23, 266, 10.1179/joc.2011.23.5.266

Brink, 2012, Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004–2009): Impact of the new carbapenem breakpoints, Surg. Infect., 13, 43, 10.1089/sur.2011.074

Yang, 2013, A ten-year surveillance for antimicrobial susceptibility of Escherichia coli and Klebsiella pneumoniae in community- and hospital-associated intra-abdominal infections in China, J. Med. Microbiol., 62, 1343, 10.1099/jmm.0.059816-0

Hawser, 2013, Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002–2010, Int. J. Antimicrob. Agents, 41, 224, 10.1016/j.ijantimicag.2012.10.014

Hoban, 2012, Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum β-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: Results from the SMART study 2009–2010, Diagn. Microbiol. Infect. Dis., 74, 62, 10.1016/j.diagmicrobio.2012.05.024

Bouchillon, 2013, Antimicrobial Susceptibility of Inpatient Urinary Tract Isolates of Gram-Negative Bacilli in the United States: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART) Program: 2009–2011, Clin. Ther., 35, 872, 10.1016/j.clinthera.2013.03.022

Hawser, 2010, Epidemiologic trends, occurrence of extended-spectrum β-lactamase production, and performance of ertapenem and comparators in patients with intra-abdominal infections: Analysis of global trend data from 2002–2007 from the SMART study, Surg. Infect., 11, 371, 10.1089/sur.2009.057

Babinchak, 2013, Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005–2010, Diagn. Microbiol. Infect. Dis., 76, 379, 10.1016/j.diagmicrobio.2013.02.031

(2010). Performance Standards for Antimicrobial Susceptibility Testing, Twenty-second Informational Supplement, Clinical Laboratory Standards Institute.

Badal, 2011, Changes in the CLSI Interpretive Criteria for Enterobacteriaceae and Ertapenem, Clin. Microbiol. Newsl., 33, 185, 10.1016/j.clinmicnews.2011.11.002

(2012). Performance Standards for Antimicrobial Susceptibility Testing, Twenty-second Informational Supplement, Clinical and Laboratory Standards Institute (CLSI).

Thông tin
Thông tin xuất bản

Pharmaceuticals

Tập 6 Số 11

1335-1346

Thông tin tác giả